Related Experiment Videos
[Identification bcr-abl fusion gene in leukemia cells with oligonucleotide microarray]
Yan Li1, Jian Huang, Jie-Ping Chen
1Department of Hematology, South-West Hospital, Chongqing 400038, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|January 6, 2005
Summary
This study demonstrates that oligonucleotide microarrays can effectively detect the bcr-abl fusion gene in leukemia cells, aiding in diagnosis and treatment decisions.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Context:
- The bcr-abl fusion gene is a key marker in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Accurate detection of this gene is crucial for diagnosis, treatment selection, and prognosis.
- Traditional detection methods can be time-consuming and complex.
Purpose:
- To evaluate the clinical application value of a designed oligonucleotide microarray for detecting the bcr-abl fusion gene.
- To optimize detection conditions for improved accuracy and efficiency.
- To assess the utility of microarray technology in leukemia diagnosis, typing, treatment selection, and prognosis.
Summary:
- Oligonucleotide probes were designed and a microarray was prepared for bcr-abl fusion gene detection.
- Total RNA was extracted, reverse-transcribed, and labeled for hybridization with the microarray.
- Optimized hybridization and elution conditions enabled successful detection of the bcr-abl fusion gene in leukemia cells.
Impact:
- Oligonucleotide microarrays show effectiveness and unique advantages for bcr-abl fusion gene detection.
- The technology holds potential for clinical application in hematology, pending further improvements.
- This method could enhance diagnostic capabilities and personalize treatment strategies for leukemia patients.